Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/147966
Title: MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC; WNT and AKT pathways
Author: Majem, Blanca
Parrilla, Alfonso
Jiménez, Carlos
Marin, Andrea
Suárez, Leticia
Castellví, Josep
Tamayo, Gabriel
Moreno, Gema
Ponce i Sebastià, Jordi
Matias-Guiu, Xavier
Alameda, Francesc
Romero, Ignacio
Sánchez, José Luis
Pérez Benavente, Asunción
Moran, Sebastian
Esteller, Manel
Reventós Puigjaner, Jaume
Rigau, Marina
Gil Moreno, Antonio
Segura, Miguel F.
Santamaría Margalef, Anna
Keywords: Apoptosi
Epigenètica
Micro RNAs
Càncer d'ovari
Apoptosis
Epigenetics
MicroRNAs
Ovarian cancer
Issue Date: 5-Jul-2019
Publisher: National Academy of Sciences
Abstract: Ovarian cancer is the most lethal gynecological malignancy due to the silent nature on its early onset and the rapid acquisition of drug resistance. Histologically heterogeneous, it includes several subtypes with different mutational landscapes, hampering the development of effective targeted therapies. Non-coding RNAs are emerging as potential new therapeutic targets in cancer. To search for a microRNA signature related to ovarian carcinomas and study its potential as effective targeted therapy, we examined the expression of 768 miRNA in a large collection of tumor samples and found miR-654-5p to be infraexpressed in ovarian serous carcinomas, the most common and aggressive type. Restoration of miR654-5p levels reduced tumor cell viability in vitro and in vivo and impaired sphere formation capacity and viability of ovarian cancer patient-derived ascitic cells ex vivo. CDCP1 and PLAGL2 oncogenes were found to be the most relevant direct miR-654-5p targets and both genes convey in a molecular signature associated with key cancer pathways relevant to ovarian tumorigenesis, such as MYC, WNT and AKT pathways. Together, we unveiled the tumor suppressor function of miR-654-5p, suggesting that its restoration or co-targeting of CDCP1 and PLAGL2 may be an effective therapeutic approach for ovarian cancer.
Note: Reproducció del document publicat a: https://doi.org/10.1038/s41388-019-0860-0
It is part of: Proceedings of the National Academy of Sciences of the United States of America - PNAS, 2019, vol. 38, p. 6035-6050
URI: http://hdl.handle.net/2445/147966
Related resource: https://doi.org/10.1038/s41388-019-0860-0
ISSN: 0027-8424
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
682225.pdf5.46 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.